Thermo Fisher Scientific Inc.(TMO) (Q2FY23)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally.
The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
It’s Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products.
Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs.
Thermo Fisher Scientific has demonstrated robust execution of its established growth strategy through the introduction of a range of impactful and innovative products. Notably, they unveiled the Thermo Scientific™ Orbitrap™ Astral™ mass spectrometer, which is a groundbreaking advancement in mass spectrometry.
Thermo Fisher Scientific stock price showed an upward trend in past 3-months. It increased by 2.64% during the period.The stock price declined by 7.56% in past 1-year. The stock has a 52- week high of $609.85 and its 52-week low is $475.77.
In the past 3 years, the stock has given returns of 33.5%. TMO has a 50-day moving Avg. and 200-day moving Avg. of $531.80 and $545.82, respectively.
This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals
– Price Performance
Stock Price Performance
No of Pages: 34
To download the previous quarter’s equity report CLICK HERE
To Download other equity/ stock reports CLICK HERE
Follow our LinkedIn page for more updates.